

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: TDM2/22 - Therapeutic Drugs

Deadline: 07.10.2022

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(85) Phenytoin	[mg/L]				38							38	37	97%									0
Samples and groups																							
Sample A1		9,57	0,60	6,2	38	CVP	9,57	0,24	20%	7,65	11,5	38	37	97%									0
(6) Immunoturbidimetry, KIMS		9,79	0,53	5,4	11	0						11											
Other					8	0						8											
							4x 2, 2x 3, 2x 5																
Sample B1		3,95	0,34	8,7	38	CVP	3,95	0,14	20%	3,16	4,74	38	37	97%									0
(1) FIA, FPIA, DELFIA		3,89	0,17	4,4	6	0						6											
(4) LIA, ILMA		4,05	0,38	9,5	13	0						13											
(6) Immunoturbidimetry, KIMS		3,92	0,40	10	11	0						11											
Other					8	0						8											
							4x 2, 2x 3, 2x 5																
(86) Carbamazepin	[mg/L]				60							60	54	90%									0
Samples and groups																							
Sample A1		10,1	0,87	8,6	60	CVP	10,1	0,27	20%	8,08	12,2	60	55	92%									0
(1) FIA, FPIA, DELFIA		10,9	1,2	11	6	0						6											
(2) EIA (EMIT, CEDIA)		10,3	0,22	2,2	9	0						9											
(4) LIA, ILMA		9,91	0,74	7,5	22	0						22											
(6) Immunoturbidimetry, KIMS		10,1	0,92	9,1	18	0						18											
Other					5	0						5											
							3x 3, 2x 5																
Sample B1		3,43	0,34	9,8	60	CVP	3,43	0,11	20%	2,74	4,12	60	56	93%									0
(1) FIA, FPIA, DELFIA		3,55	0,33	9,3	6	0						6											
(2) EIA (EMIT, CEDIA)		3,39	0,28	8,3	9	0						9											
(4) LIA, ILMA		3,39	0,27	7,9	22	0						22											
(6) Immunoturbidimetry, KIMS		3,41	0,45	13	18	0						18											
Other					5	0						5											
							3x 3, 2x 5																
(88) Valproic acid	[mg/L]				84							84	80	95%									0
Samples and groups																							
Sample A1		35,3	3,1	8,9	84	CVP	35,3	0,84	20%	28,2	42,4	84	81	96%									0
(1) FIA, FPIA, DELFIA		36,1	1,9	5,1	13	0						13											
(2) EIA (EMIT, CEDIA)		36,6	3,4	9,4	17	0						17											
(4) LIA, ILMA		33,9	3,3	9,8	31	0						31											
(6) Immunoturbidimetry, KIMS		35,5	2,3	6,4	23	0						23											
Sample B1		127	7,9	6,2	84	CVP	127	2,1	20%	101	153	84	83	99%									0
(1) FIA, FPIA, DELFIA		128	3,6	2,8	13	0						13											
(2) EIA (EMIT, CEDIA)		130	8,6	6,6	17	0						17											
(4) LIA, ILMA		126	10	8,1	31	0						31											
(6) Immunoturbidimetry, KIMS		125	7,2	5,7	23	0						23											
(83) Primidone	[mg/L]				8							8	8	100%									0
Samples and groups																							
Sample A1		9,94	0,83	8,4	8	CVP	9,94	0,63	24%	7,55	12,4	8	8	100%									0
Other					8	0						8											
							1x 2, 4x 3, 3x 5																
Sample B1		4,32	0,58	14	8	CVP	4,32	0,44	24%	3,28	5,36	8	8	100%									0
Other					8	0						8											
							1x 2, 4x 3, 3x 5																

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: TDM2/22 - Therapeutic Drugs

Deadline: 07.10.2022

Test	[unit]	Comparability										Traceability											
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}	
(93) Methotrexate					11							11	11	100%									0
Samples and groups	[µmol/L]																						
Sample A2		3,21	0,33	10	11	CVP	3,21	0,25	30%	2,24	4,18	11	11	100%									0
(4) LIA, ILMA		3,22	0,17	5,4	9	0						9											
Other					2	0						2											
						2x2																	
Sample B2		1,10	0,07	6,3	11	CVP	1,1	0,052	30%	0,77	1,43	11	11	100%									0
(4) LIA, ILMA		1,10	0,04	4,0	9	0						9											
Other					2	0						2											
						2x2																	
(92) Vankomycin					69							69	68	99%									0
Samples and groups	[mg/L]																						
Sample A2		11,0	0,82	7,5	69	CVP	11	0,24	28%	7,92	14,1	69	68	99%									0
(1) FIA, FPIA, DELFIA		10,7	0,80	7,4	10	0						10											
(2) EIA (EMIT, CEDIA)		10,2	1,3	13	8	0						8											
(4) LIA, ILMA		11,3	0,63	5,6	26	0						26											
(6) Immunoturbidimetry, KIMS		11,0	0,55	5,0	25	0						25											
Sample B2		15,9	1,2	7,3	69	CVP	15,9	0,34	28%	11,4	20,4	69	68	99%									0
(1) FIA, FPIA, DELFIA		16,0	0,51	3,2	10	0						10											
(2) EIA (EMIT, CEDIA)		14,8	1,9	13	8	0						8											
(4) LIA, ILMA		16,5	1,1	6,7	26	0						26											
(6) Immunoturbidimetry, KIMS		15,8	0,93	5,9	25	0						25											

st_kn_np

End of report

Printed: 14.10.2022